title: Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?
authors.affiliation: a Department of Medicine , Section of Hematology/Oncology, The University of Chicago Medical Center , Chicago , IL , USA.
authors.forename: Hongtao
authors.initials: H
authors.lastname: Liu
authors.affiliation: a Department of Medicine , Section of Hematology/Oncology, The University of Chicago Medical Center , Chicago , IL , USA.
authors.forename: Wendy
authors.initials: W
authors.lastname: Stock
mesh_terms: D000066491:Clinical Decision-Making; D003131:Combined Modality Therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000628:therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis*; D012074:Remission Induction